Update: All Trials en de Nederlandse pensioenfondsen

Iets minder dan een maand geleden plaatste ik het bericht “AllTrials en de Nederlandse pensioenfondsen” naar aanleiding van het nieuws dat 85 pensioenfondsen hun steun hebben uitgesproken voor het AllTrials initiatief. 85 pension funds and asset managers call for clinical trials transparency #alltrials @bengoldacre http://t.co/Xb0alnYM7y — Martin Barrow (@MartinBarrow) July

Continue Reading

AllTrials en de Nederlandse pensioenfondsen

Funds Join Campaign to Pressure Pharma to Disclose Trial Data http://t.co/em6P7DPaz8 via @WSJ #AllTrials — Vincent Bontrop (@Bontrop) August 13, 2015 Massive pension funds pressure pharma companies to disclose trial data http://t.co/HUYnZKxzV1 #alltrials #openscience pic.twitter.com/UvxMTBvqKq — Open Science (@openscience) August 5, 2015 Maar hoe zit dat eigenlijk met de Nederlandse

Continue Reading

Reporting of Clinical Trial Results

“Thousands of clinical trials have not reported their results; some have not even been registered. Information on what was done and what was found in these trials could be lost forever to doctors and researchers, leading to bad treatment decisions, missed opportunities for good medicine, and trials being repeated. The contributions of the hundreds of thousands of patients who took part in those trials remain unused and unusable. All trials past and present should be registered, and the full methods and the results reported.” (AllTrials, 2014)

Continue Reading

What doctors don’t know about the drugs they prescribe | Ben Goldacre | TEDMED

When a new drug gets tested, the results of the trials should be published for the rest of the medical world — except much of the time, negative or inconclusive findings go unreported, leaving doctors and researchers in the dark. In this impassioned talk, Ben Goldacre explains why these unreported instances of negative data are especially misleading and dangerous.

Continue Reading